FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 8, 2026 192 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Prevention and Early Detection of Gastrointestinal Cancers Take on New Importance... June 27, 2024 FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma August 30, 2021 5 questions the NHS Workforce Plan for England needs to answer June 27, 2023 Additional Translations of the ESMO Patient Guides Now Available in the Croatian May 18, 2026 Load more HOT NEWS Ifosfamide May Be Treatment of Choice for Some People with Ewing... Does Too Much Fructose Help Colorectal Cancers Grow? COVID-19 Testing: What you need to know. The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights...
